Product Center
HRK-X Selected for Jiangsu Province's 2024 Innovative Pharmaceutical Equipment Special Award List!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-03-08
- Views:
(Summary description)Recently, the list of innovative drug and device award projects of the special fund for the construction of a strong manufacturing province in Jiangsu Province in 2024 was released, Ab&B Bio-Tech CO.,LTD. JS's self-developed quadrivalent influenza virus subunit vaccine (HRK-X), a new class of drugs, was selected into the list of approved innovative drugs in 2023.
HRK-X Selected for Jiangsu Province's 2024 Innovative Pharmaceutical Equipment Special Award List!
(Summary description)Recently, the list of innovative drug and device award projects of the special fund for the construction of a strong manufacturing province in Jiangsu Province in 2024 was released, Ab&B Bio-Tech CO.,LTD. JS's self-developed quadrivalent influenza virus subunit vaccine (HRK-X), a new class of drugs, was selected into the list of approved innovative drugs in 2023.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-03-08 16:20
- Views:
Recently, the list of innovative drug and device award projects of the special fund for the construction of a strong manufacturing province in Jiangsu Province in 2024 was released, Ab&B Bio-Tech CO.,LTD. JS's self-developed quadrivalent influenza virus subunit vaccine (HRK-X), a new class of drugs, was selected into the list of approved innovative drugs in 2023.
As a preventive Category 1 biological product, HRK-X features a proprietary influenza virus subunit extraction process. This technology not only ensures the high purity of HA and NA proteins from all four vaccine strains and vaccine safety, but also demonstrates excellent immunogenicity. The product's quality standards exceed both Chinese Pharmacopoeia and EU Pharmacopoeia requirements, filling a domestic gap in this field!
Recently, at the Entrepreneurship Spirit Promotion Conference for Advancing New Industrialization, the Pharmaceutical High-Tech Zone (Gaogang District) awarded Mr. An Youcai, Chairman and General Manager of Ab&B Bio-Tech Co., Ltd., the honorary title of "Top Ten Star Entrepreneurs"! This recognition fully acknowledges Mr. An's and Ab&B Bio's pioneering spirit in developing and industrializing innovative human vaccines - their boldness to venture and innovate!
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
